Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab quality-of-life study in chronic spontaneous urticaria refractory to H1 antihistamines
2014-005424-97Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Novartis. Started Jun 2015; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2014-005424-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005424-97.